Today's News

• Get these news in RSS

• BTG Receives First European Regulatory Approval for DigiFab(TM) Feb 4 2010

  BTG plc (LSE: BGC), the specialty pharmaceuticals company, today announces that Swissmedic, the Swiss Agency for Therapeutic Products, has approved the antidote DigiFab(TM) for the treatment of patients with life-threatening digitalis intoxication. DigiFab(TM) is already available in Switzerland under a conditional marketing authorisation and in ot

• Aspen Receives US $1 Million In Transfer of Technology Agreement Feb 3 2010

  Eli Lilly today announced the US$1 million milestone payment to Aspen, South Africa?s leading pharmaceutical manufacturer, as part of the joint collaboration on expanding access to medicines to treat multidrug-resistant tuberculosis (MDR-TB). The milestone is part of a Transfer of Technology agreement between Aspen and Lilly, initiated in 2003 u

• Apeiron and GSK sign an exclusive licence agreement for Apeiron's therapeutic enzyme project APN01 Feb 3 2010

  Apeiron Biologics AG (Apeiron) today announced the signing of an agreement granting GlaxoSmithKline (GSK) exclusive rights to APN01 (recombinant human Angiotensin Converting Enzyme 2, rhACE2), an enzyme biotherapeutic currently in Phase 1 development for the treatment of the Acute Respiratory Distress Syndrome (ARDS). Under the terms of the agreem

• Neurosearch A/S (NEUR.CO) Announces Positive Top-line Results from Phase III Huntexil(R) Study in Huntington's Disease Feb 3 2010

  NeuroSearch (NEUR) today reported positive top-line results from the MermaiHD study, the European Phase III study with Huntexil® (pridopidine) in Huntington's disease. The MermaiHD study met the primary endpoint to show an effect on voluntary motor function. In addition, data from the 437 Huntington patients, who participated in the study (= ITT

• Other News

• U.S. FDA Approves Labopharm (DDS.TO)'s Antidepressant Trazodone Feb 3 2010

• Auxilium Pharmaceuticals (AUXL) Announces FDA Approval for XIAFLEX(TM) for the Treatment of Dupuytren's Contracture Feb 3 2010

• EUR 2 Million Cash Injection to Enlarge Portfolio, Develop Markets Feb 3 2010